大北農(002385.SZ):6月銷售收入環比增9.56%、同比增6.68%
格隆匯7月7日丨大北農(002385.SZ)公佈2022年6月份生豬銷售情況簡報,公司控股及參股公司銷售情況如下:2022年6月銷售生豬28.58萬頭,銷售收入5.27億元。其中銷售收入環比增長9.56%,同比增長6.68%;銷售數量環比增長1.93%,同比增長0.49%;商品肥豬出欄均重118.94公斤,銷售均價16.73元/公斤。
2022年1-6月,累計銷售生豬198.32萬頭,同比增長19.23%。累計銷售收入29.25億元,同比增長-35.09%。
2022年1-6月,公司生豬銷售收入同比下降是因為國內生豬市場行情變化所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.